Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The use of maintenance treatments in myeloma patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.03.11
Views: 6985

Prof Antonio Palumbo - Molinette Hospital, Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA

Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib (Velcade) with thalidomide as maintenance treatments, a trial investigating the use of pomalidomide in patients refractory to both bortezomib and lenalidomide, research into the use of bisphosphonates and a trial showing the drawbacks of allogeneic stem cell transplants.

Prof Antonio Palumbo speaks about the research he presented which highlights the benefits of drug combinations followed by lenalidomide or bortezomib and thalidomide maintenance treatments. These trials have produced extremely positive complete response rates in patients aged 65-75, offering clinicians with an alternative to stem cell transplants.

Related videos

follow us

War on Cancer 2018

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation